Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 20 | 2024 | 5686 | 1.900 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2024 | 4034 | 1.640 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2023 | 545 | 1.410 |
Why?
|
| Melanoma | 13 | 2023 | 5510 | 1.250 |
Why?
|
| Immunotherapy | 17 | 2023 | 4445 | 1.230 |
Why?
|
| Oncolytic Viruses | 3 | 2022 | 327 | 0.840 |
Why?
|
| Carcinoma, Merkel Cell | 5 | 2023 | 300 | 0.760 |
Why?
|
| Prodrugs | 1 | 2022 | 268 | 0.740 |
Why?
|
| Riluzole | 3 | 2023 | 55 | 0.420 |
Why?
|
| Kidney Transplantation | 2 | 2024 | 4251 | 0.390 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2022 | 3143 | 0.350 |
Why?
|
| Oncolytic Virotherapy | 4 | 2023 | 498 | 0.340 |
Why?
|
| Kidney Neoplasms | 2 | 2022 | 4262 | 0.310 |
Why?
|
| Neoplasms | 10 | 2023 | 21683 | 0.300 |
Why?
|
| Microsatellite Instability | 2 | 2021 | 684 | 0.280 |
Why?
|
| Injections, Intralesional | 3 | 2020 | 276 | 0.250 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 13695 | 0.240 |
Why?
|
| Cytokines | 1 | 2019 | 7322 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2024 | 1855 | 0.220 |
Why?
|
| Goats | 1 | 2022 | 171 | 0.220 |
Why?
|
| Radiosurgery | 3 | 2016 | 1329 | 0.200 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 233 | 0.190 |
Why?
|
| Glutamates | 1 | 2022 | 398 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 9274 | 0.190 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2020 | 371 | 0.160 |
Why?
|
| Humans | 42 | 2024 | 744343 | 0.150 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 3586 | 0.150 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2019 | 475 | 0.140 |
Why?
|
| Ultraviolet Rays | 1 | 2021 | 1060 | 0.140 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2018 | 211 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2015 | 8863 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2022 | 1405 | 0.130 |
Why?
|
| Medicare Part D | 1 | 2020 | 328 | 0.130 |
Why?
|
| Interferons | 1 | 2018 | 706 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2309 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2023 | 4479 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2023 | 8642 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 11524 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2020 | 10252 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 1372 | 0.110 |
Why?
|
| Prescription Drugs | 1 | 2020 | 595 | 0.110 |
Why?
|
| Cranial Irradiation | 1 | 2015 | 401 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2938 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 738 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 2019 | 1904 | 0.100 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 570 | 0.100 |
Why?
|
| Biological Products | 1 | 2020 | 860 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 3798 | 0.100 |
Why?
|
| Craniotomy | 1 | 2015 | 729 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1526 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2018 | 3002 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2727 | 0.090 |
Why?
|
| Spinal Neoplasms | 1 | 2016 | 760 | 0.090 |
Why?
|
| Retrospective Studies | 9 | 2023 | 77449 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 1333 | 0.080 |
Why?
|
| Disease Progression | 3 | 2020 | 13284 | 0.080 |
Why?
|
| Prognosis | 4 | 2023 | 29063 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2020 | 4397 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 7913 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7279 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2019 | 3209 | 0.070 |
Why?
|
| Comorbidity | 1 | 2020 | 10388 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5256 | 0.060 |
Why?
|
| Middle Aged | 10 | 2020 | 213383 | 0.060 |
Why?
|
| Philadelphia | 1 | 2023 | 266 | 0.060 |
Why?
|
| Aged | 9 | 2020 | 163280 | 0.060 |
Why?
|
| Proteins | 1 | 2018 | 6103 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2020 | 63114 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 57776 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2020 | 1770 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2023 | 3474 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5221 | 0.050 |
Why?
|
| Male | 11 | 2023 | 350118 | 0.050 |
Why?
|
| Acetamides | 1 | 2023 | 249 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 40561 | 0.050 |
Why?
|
| Containment of Biohazards | 1 | 2020 | 37 | 0.050 |
Why?
|
| Niacinamide | 1 | 2023 | 417 | 0.050 |
Why?
|
| Quality of Life | 1 | 2022 | 12804 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2023 | 892 | 0.050 |
Why?
|
| Adult | 8 | 2023 | 214055 | 0.050 |
Why?
|
| Oximes | 1 | 2022 | 311 | 0.050 |
Why?
|
| Squalene | 1 | 2019 | 32 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2023 | 528 | 0.040 |
Why?
|
| Animals | 5 | 2023 | 168757 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2022 | 371 | 0.040 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2019 | 154 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 648 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 6538 | 0.040 |
Why?
|
| Female | 9 | 2022 | 380194 | 0.040 |
Why?
|
| Methylprednisolone | 1 | 2020 | 387 | 0.040 |
Why?
|
| United States | 3 | 2021 | 69872 | 0.040 |
Why?
|
| Skin | 2 | 2023 | 4364 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2022 | 412 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2018 | 184 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 11031 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 403 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 712 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 841 | 0.040 |
Why?
|
| Imidazoles | 1 | 2022 | 1206 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 459 | 0.030 |
Why?
|
| Prednisone | 1 | 2020 | 1574 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 2020 | 743 | 0.030 |
Why?
|
| Drugs, Generic | 1 | 2020 | 421 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2019 | 1200 | 0.030 |
Why?
|
| Autophagy | 1 | 2022 | 1300 | 0.030 |
Why?
|
| Seasons | 1 | 2019 | 1493 | 0.030 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2017 | 290 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 1607 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2023 | 1972 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2018 | 1041 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1038 | 0.030 |
Why?
|
| Drug Costs | 1 | 2020 | 1105 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 2043 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 3913 | 0.020 |
Why?
|
| Mice | 3 | 2023 | 81183 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 3772 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 934 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2019 | 3023 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 6622 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2019 | 1479 | 0.020 |
Why?
|
| Vaccination | 1 | 2019 | 3278 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 5535 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2020 | 2348 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 16689 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 4665 | 0.020 |
Why?
|
| Time Factors | 2 | 2019 | 40075 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 3743 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 3610 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6895 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5172 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 18029 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9239 | 0.010 |
Why?
|
| Patient Selection | 1 | 2016 | 4215 | 0.010 |
Why?
|
| Risk Factors | 2 | 2023 | 72290 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.010 |
Why?
|
| Medicare | 1 | 2019 | 6566 | 0.010 |
Why?
|
| Lung | 1 | 2019 | 9856 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 9959 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 25043 | 0.010 |
Why?
|
| Inflammation | 1 | 2018 | 10638 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 29786 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13102 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23403 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 56430 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2016 | 53288 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 85781 | 0.010 |
Why?
|
Concepts
(148)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(44)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_